Get 20% lifetime commission for referring investors to digrin.com
here.
Relmada Therapeutics, Inc. (RLMD) Financials
RLMD Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 219.1 million | 12.5 million |
| March 31, 2026 | 235.4 million | 16.6 million |
| Dec. 31, 2025 | 94.0 million | 7.5 million |
| Sept. 30, 2025 | 14.9 million | 5.4 million |
RLMD Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -9.6 million | -1.8 million |
| March 31, 2026 | -15.1 million | 3.6 million |
| Dec. 31, 2025 | -14.6 million | 3.2 million |
| Sept. 30, 2025 | -6.7 million | 3.6 million |
RLMD Net Income
No data available :(
RLMD Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 217.7 million | - | - |
| March 31, 2026 | 234.0 million | - | - |
| Dec. 31, 2025 | 93.0 million | - | - |
| Sept. 30, 2025 | 13.9 million | - | - |
RLMD Shares Outstanding
RLMD Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | - | 8.4 million | 6.6 million | - |
| March 31, 2026 | - | 8.1 million | 11.4 million | - |
| Dec. 31, 2025 | - | 8.1 million | 12.3 million | - |
| Sept. 30, 2025 | - | 4.0 million | 6.3 million | - |
RLMD Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | - |
| Dec. 31, 2025 | - | - |
| Sept. 30, 2025 | - | - |
RLMD
Price: $4.77
52 week price:
Earnings Per Share: -0.91 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 144200
Market Capitalization: 476.8 million